Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis

Main Article Content

Bo Ding
Yin Lai
Yanming Lu


Anti-AD Treatment, Atopic Dermatitis, Dupilumab, Mite Allergen-specific Immunotherapy, Immunotherapy


Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that manifests in skin dryness, severe itching, and eczema, and can significantly impact a patient’s quality of life. Current treatment regimens do not prevent the recurrence of the disease and are associated with adverse effects. Here, we report two cases of moderate-to-severe AD in children that were treated with dupilumab, a dual inhibitor of IL-4 and IL-13 signaling, in combination with mite allergen-specific immunotherapy.

Case summary: Both patients presented with the diagnosis of AD that was not adequately controlled by the conventional treatment regimen, including topical corticosteroids (TCS), topical calcineurin inhibitors, emollients, and the traditional Chinese medicine treatments. In both patients, AD-associated skin irritation impacted the quality of life, disturbed sleep patterns, and caused stress and anxiety.

Patients received treatment with dupilumab and mite allergen-specific immunotherapy in addition to the baseline treatment regimen of external glucocorticoids (TCS) and oral antihistamines. Nine months after beginning of treatment, clinical symptoms, signs, medication scores, and evaluation scale scores of both children significantly improved, and the treatment was associated with an overall good tolerance.

Conclusion: A combination of dupilumab and mite allergen-specific immunotherapy in addition to the standard anti-AD treatment improves clinical symptoms and is not associated with increased incidence of adverse effects.

Abstract 159 | PDF Downloads 194 HTML Downloads 15 XML Downloads 8


1. Atopic Dermatitis Working Group, Immunology Group, Chinese Society of Dermatology. Guideline for diagnosis and treatment of atopic dermatitis in China. Chin J Dermatol. 2020;53(2): 81–8. 10.35541/cjd.20191000

2. Giavina-Bianchi MH, Giavina-Bianchi P, Rizzo LV. Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: Case report. Einstein Sao Paulo Braz. 2019;17(4):eRC4599. 10.31744/einstein_journal/2019RC4599

3. Lee J, Lee H, Noh S, Bae BG, Shin JU, Park CO, et al. Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopicd. Yonsei Med J. 2016;57(2):393–8. 10.3349/ymj.2016.57.2.393

4. Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: An update. Exp Ther Med. 2019;17(2):1061–7. 10.3892/etm.2018.6989

5. Kulthanan K, Tuchinda P, Nitiyarom R, Chunharas A, Chantaphakul H, Aunhachoke K, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol. 2021;39(3):145–55.

6. Bieber T. Atopic dermatitis: An expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1): 21–40. 10.1038/s41573-021-00266-6

7. Tam H, Calderon MA, Manikam L, Nankervis H, García Núñez I, Williams HC, et al. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst Rev. 2016;2(2):CD008774. 10.1002/14651858.CD008774.pub2

8. Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–68. 10.1111/exd.13911

9. Weller K, Soost S, Worm M, Maurer M, Zuberbier T. Atopic dermatitis and allergic rhinitis—Do co-effects in therapy exist? J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2012;10(4): 221–36; quiz 238–9. 10.1111/j.1610-0387.2011.07885.x

10. Giavina-Bianchi M, Giavina-Bianchi P. Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis. Einstein Sao Paulo Braz. 2021;19:eRC6064. 10.31744/einstein_journal/2021RC6064

11. Davari DR, Nieman EL, McShane DB, Morrell DS. Current Perspectives on the Systemic Management of Atopic Dermatitis. J Asthma Allergy. 2021;14:595–607. 10.2147/JAA.S287638

12. Chan TC, Wu NL, Wong LS, Cho YT, Yang CY, Yu Y, et al. Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. J Formos Med Assoc Taiwan Yi Zhi. 2021;120(1 Pt 2):429–42. 10.1016/j.jfma.2020.06.008

13. Wei D, Ying G a. O. Research advances in the treatment of moderate-to-severe atopic dermatitis in children with dupilumab. Chin J Pract Pediatr. 2021;36(9):660.

14. Dong W lan, An J, Yu M, Yin P, Xu T ling, Liu B, et al. The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019. World Allergy Organ J. 2021;14(11):100604. 10.1016/j.waojou.2021.100604

15. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A-systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110–7. 10.1016/j.jaci.2013.02.044

16. Hoshino M, Akitsu K, Kubota K, Ohtawa J. Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis. Allergol Int Off J Jpn Soc Allergol. 2022;71(4):490–7. 10.1016/j.alit.2022.05.010

17. Corren J, Saini SS, Gagnon R, Moss MH, Sussman G, Jacobs J, et al. Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: A randomized trial. J Asthma Allergy. 2021;14:1045–63. 10.2147/JAA.S318892

18. Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: A consensus document. Section II: Tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(1_suppl):10S–16S. 10.1177/1203475418803628

19. Zhai LL, Savage KT, Qiu CC, Jin A, Valdes-Rodriguez R, Mollanazar NK. Chronic pruritus responding to dupilumab—-A case series. Med Basel Switz. 2019;6(3):72. 10.3390/medicines6030072

20. Sastre J, Dávila I. Dupilumab: A new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28(3):139–50. 10.18176/jiaci.0254

21. Castagnoli R, De Filippo M, Votto M, Marseglia A, Montagna L, Marseglia GL, et al. An update on biological therapies for pediatric allergic diseases. Minerva Pediatr. 2020;72(5): 364–71. 10.23736/S0026-4946.20.05993-9

22. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. 10.1001/jamadermatol.2019.3336

23. Regeneron Pharmaceuticals. A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients, ≥6 years to ˂12 years of age, with severe atopic dermatitis [Internet].; 2020 Jul [cited 2022 Dec 29]. Report No.: NCT03345914. Available from:

24. Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85–96. 10.1111/bjd.18476

25. Guo Y, Cai Y. Immune mechanism and clinical research progress in the treatment of atopic dermatitis with dupilumab. China J Lepr Skin Dis. 2018;34(2):125–8.

26. dupixent_fpi.pdf [Internet]. [cited 2022 Dec 30]. Available from:

27. Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment-resistant atopic dermatitis: Challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181–92. 10.2147/CCID.S163814

28. Kim YJ, Lee MY, Won CH. Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients. Asia Pac Allergy. 2022;12(1):e1. 10.5415/apallergy.2022.12.e1